- Home
- VIR vs PRME Comparison
VIR vs PRME Comparison
Compare VIR & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- PRME
- Stock Information
- Founded
- VIR 2016
- PRME 2019
- Country
- VIR United States
- PRME United States
- Employees
- VIR N/A
- PRME N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- VIR Health Care
- PRME Health Care
- Exchange
- VIR Nasdaq
- PRME Nasdaq
- Market Cap
- VIR 706.4M
- PRME 624.0M
- IPO Year
- VIR 2019
- PRME 2022
- Fundamental
- Price
- VIR $4.38
- PRME $3.22
- Analyst Decision
- VIR Strong Buy
- PRME Buy
- Analyst Count
- VIR 8
- PRME 6
- Target Price
- VIR $30.25
- PRME $8.88
- AVG Volume (30 Days)
- VIR 1.0M
- PRME 3.9M
- Earning Date
- VIR 08-06-2025
- PRME 08-07-2025
- Dividend Yield
- VIR N/A
- PRME N/A
- EPS Growth
- VIR N/A
- PRME N/A
- EPS
- VIR N/A
- PRME N/A
- Revenue
- VIR $19,000,000.00
- PRME $4,961,000.00
- Revenue This Year
- VIR N/A
- PRME $126.92
- Revenue Next Year
- VIR $0.56
- PRME $87.32
- P/E Ratio
- VIR N/A
- PRME N/A
- Revenue Growth
- VIR N/A
- PRME 739.42
- 52 Week Low
- VIR $4.16
- PRME $1.11
- 52 Week High
- VIR $14.45
- PRME $5.17
- Technical
- Relative Strength Index (RSI)
- VIR 35.16
- PRME 41.41
- Support Level
- VIR $4.33
- PRME $3.09
- Resistance Level
- VIR $4.57
- PRME $3.88
- Average True Range (ATR)
- VIR 0.22
- PRME 0.32
- MACD
- VIR -0.02
- PRME -0.12
- Stochastic Oscillator
- VIR 21.53
- PRME 8.23
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.